Lenalid 10mg Capsule

Most side effects of Lenalid 10mg Capsule do not require medical attention as they may disappear as your body adjusts to the medicine. In case these side effects become worse, consult your doctor immediately. This medicine may lower red and white blood cell counts, raising the risk of infections or bleeding. Avoid activities that could cause bleeding and limit contact with people who are ill. Regular blood tests are needed to monitor your blood cells during treatment. Common side effects are:

• Cough  
• Nausea  
• Sore throat 
• Vomiting  
• Weakness  
• Dizziness 
• Fever 
• Decrease in white blood cell count
• Tiredness
• Swelling
• Respiratory disorder
• Bleeding gums
• Blood clots
• Decreased calcium level in the blood
• Inflammation of the throat and nasal passages
  
• Tremor

• Follow your doctor's instructions on the dosage and duration of this medication.
• It can be taken with or without food.

• Lenalid 10mg Capsule, a thalidomide analogue, is an immunomodulatory agent possessing immunomodulatory and antiangiogenic properties.
• Lenalidomide 10mg works to inhibit the secretion of pro-inflammatory cytokines and increases the secretion of anti-inflammatory cytokines from peripheral blood mononuclear cells. 
• Lenalid 10mg inhibits cell proliferation with varying effectiveness (IC50s) in some but not all cell lines.
• Lenalid 10mg Capsule is effective in inhibiting the growth of Namalwa cells (a human B cell lymphoma cell line with a deletion of one chromosome 5) but is much less effective in inhibiting the growth of KG-1 cells (human myeloblastic cell line, also with a deletion of one chromosome 5) and other cell lines without chromosome 5 deletions.
• It does not prolong the QTc interval.  

• ​If you forget to take a dose of Lenalid Capsule, consult your doctor.
• Don’t double up the next dose to cope with the missed one unless your doctor recommends it.​​
  

• Chen, N., Zhou, S., Palmisano, M. (2017). Clinical pharmacokinetics and Pharmacodynamics of lenalidomide. Clinical Pharmacokinetics, 56(2), 139–152. Monteiro, M. M., Ferreira, F. V., Santos, J. P., Lima, J. A., & de Almeida, M. F. (2023). Bioequivalence of lenalidomide 10 mg capsule (Eurofarma Laboratórios S/A) to Revlimid® 10 mg under fasting conditions in healthy subjects. Brazilian Journal of Pharmaceutical Sciences, 
• Preston, S., Anderson, N. E., Basile, V. S., Holton, T., Schmid, K., Graham, A., Fok, A., Taylor, A., & Taylor, B. V. (2024). A phase 1b, dose-finding Study of lenalidomide in patients with anti-MAG neuropathy: Safety, tolerability, and maximum tolerated dose. European Journal of Neurology, 31(3), 560–568.
• Syed, S., Esseltine, D. L., Reeves, J., Abolhassani, S., Akhter, A., Sarin, N., Lozanski, G., Benson, D. M., Baiocchi, R. A., & Hofmeister, C. C. (2024). A Phase I trial evaluating the addition of lenalidomide to ruxolitinib and methylprednisolone in patients with relapsed or refractory multiple myeloma. Blood, 142(Supplement 1), 4753–4753.
• Washington University School of Medicine. (2025). Lenalidomide treatment for inflammation and cognition in early Alzheimer’s disease [Interventional clinical trial protocol]. ClinicalTrials.gov.